Strategic Technology Licensing with CEVEC Pharmaceuticals GmbH
Inno Biologics entered into a collaborative agreement with CEVEC Pharmaceuticals GmbH, a German company specialising in the development of therapeutic proteins using a newly developed expression system based on human amniocytes – CEVEC's Amniocyte Production (CAPTM) technology, offering significant advantages over existing production technology.
The CAPTM cell line offers stable and higher expression of human proteins and cell density. CEVEC's innovative technology will be used by Inno Biologics to provide cutting-edge technology to its clients for developing production cell line and biopharmaceutical products.
Smart Partnership with Boehringer Ingelheim
Inno Biologics has entered into a 10-year cooperation agreement with Boehringer Ingelheim to have non-exclusive access to Boehringer Ingelheim's comprehensive manufacturing technology platform for biopharmaceutical production. Boehringer Ingelheim will be positioned as the preferred partner for large-scale biomanufacturing for the client, if desired by the client. Inno Biologics' clients can access Boehringer Ingelheim platform technologies and its established systems in various stages of bioprocessing and biomanufacturing.
Technology Licensing with Centre of Molecular Immunology, Cuba (CIM)
Inno Biologics signed an agreement to license technology from the Cuba's Centre for Molecular Immunology (CIM) to reduce the human anti-mouse antibody (HAMA) response in patients receiving chimeric antibodies. Inno Biologics has a non-exclusive license to use CIM's technology in all countries except in Cuba.
Inno Biologics received the BioNexus status in 2006as one of the first wave leading biotechnology companies in Malaysia. It is a recognition awarded by the Malaysian Government to qualified companies that participate in and undertake value-added biotechnology businesses. With the BioNexus status, Inno Biologics will enjoy a set of incentives and privileges contained within the BioNexus Bill of Guarantees.